Oncotelic Therapeutics Inc
OTC:OTLC
Intrinsic Value
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one OTLC stock under the Base Case scenario is 0.016 USD. Compared to the current market price of 0.036 USD, Oncotelic Therapeutics Inc is Overvalued by 56%.
Valuation Backtest
Oncotelic Therapeutics Inc
Run backtest to discover the historical profit from buying and selling OTLC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Oncotelic Therapeutics Inc's business.
What risks and challenges
does Oncotelic Therapeutics Inc face in the near future?
Summarize the latest earnings report
of Oncotelic Therapeutics Inc.
Provide P/E
for Oncotelic Therapeutics Inc and its competitors.
Balance Sheet Decomposition
Oncotelic Therapeutics Inc
Current Assets | 365.5k |
Cash & Short-Term Investments | 268k |
Receivables | 19k |
Other Current Assets | 78.5k |
Non-Current Assets | 29.7m |
Long-Term Investments | 22.6m |
Intangibles | 7.1m |
Current Liabilities | 17.1m |
Accounts Payable | 2m |
Accrued Liabilities | 772.2k |
Short-Term Debt | 9.7m |
Other Current Liabilities | 4.7m |
Non-Current Liabilities | 435.6k |
Long-Term Debt | 899.1k |
Other Non-Current Liabilities | -463.5k |
Earnings Waterfall
Oncotelic Therapeutics Inc
Revenue
|
70k
USD
|
Operating Expenses
|
-975.5k
USD
|
Operating Income
|
-905.5k
USD
|
Other Expenses
|
-11.6m
USD
|
Net Income
|
-12.5m
USD
|
Free Cash Flow Analysis
Oncotelic Therapeutics Inc
What is Free Cash Flow?
OTLC Profitability Score
Profitability Due Diligence
Oncotelic Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Oncotelic Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
OTLC Solvency Score
Solvency Due Diligence
Oncotelic Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Score
Oncotelic Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OTLC Price Targets Summary
Oncotelic Therapeutics Inc
Ownership
OTLC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OTLC Price
Oncotelic Therapeutics Inc
Average Annual Return | -7.51% |
Standard Deviation of Annual Returns | 55.19% |
Max Drawdown | -95% |
Market Capitalization | 14.3m USD |
Shares Outstanding | 399 184 000 |
Percentage of Shares Shorted | 2.5% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Agoura Hills, California and currently employs 16 full-time employees. The firm is engaged in the development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. ArtiVeda/ArtiShield is a natural derivative from the plant Artemisia. Artemisinin derivatives are used to treat malaria. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with focus on childhood leukemia.
Contact
IPO
Employees
Officers
The intrinsic value of one OTLC stock under the Base Case scenario is 0.016 USD.
Compared to the current market price of 0.036 USD, Oncotelic Therapeutics Inc is Overvalued by 56%.